Inozyme Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>IP</div>
INZY -- USA Stock  

USD 21.93  0.78  3.69%

Inozyme Stock News module provides quick insight into current market opportunities from investing in Inozyme Pharma. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Inozyme Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly. Please see Inozyme Pharma Hype Analysis, Inozyme Pharma Correlation and Inozyme Pharma Performance.
Search Today's Stock News ... 
Inozyme Pharma stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Inozyme daily returns and investor perception about the current pice of Inozyme Pharma as well as its diversification or hedging effects on your existing portfolios.
Acquisition by Basso Stephen of 41794 shares of Inozyme Pharma subject to Rule 16b-3
Filed transaction by Inozyme Pharma Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Inozyme insider trading alert for grant of stock option (right to buy) by Basso Stephen, SVP Finance (PFO), on 14th of January 2021. This event was filed by Inozyme Pharma Inc with SEC on 2021-01-14. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   

Cash Flow from Operations

Cash Flow from Operations Comparative Analysis

Inozyme Pharma is currently under evaluation in cash flow from operations category among related companies. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.


Inozyme Pharma Related Equities

DTILPrecision Biosciences   6.87   
EARSAuris Medical   5.72   
DVAXDynavax Technologies   3.30   
DNLIDenali Therapeutics   3.26   
DRNADicerna Pharmaceutic   3.09   
EDITEditas Medicine   1.14   
NKNantkwest Inc CS   0.83   
DMACDiamedica Therapeutics   0.64   
DYAIDyadic International   1.04   
EQEquillium   4.50   
Please see Inozyme Pharma Hype Analysis, Inozyme Pharma Correlation and Inozyme Pharma Performance. Note that the Inozyme Pharma information on this page should be used as a complementary analysis to other Inozyme Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Inozyme Pharma Stock analysis

Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance